The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(R)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5H)-one ID: ALA4482864
Cas Number: 2097416-76-5
PubChem CID: 129116690
Product Number: A414127, Order Now?
Max Phase: Preclinical
Molecular Formula: C24H24F2N8O2
Molecular Weight: 494.51
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: COC[C@H]1Cn2cc(-c3nc(Nc4ccnn4C)ncc3C)nc2C(=O)N1Cc1ccc(F)c(F)c1
Standard InChI: InChI=1S/C24H24F2N8O2/c1-14-9-27-24(30-20-6-7-28-32(20)2)31-21(14)19-12-33-11-16(13-36-3)34(23(35)22(33)29-19)10-15-4-5-17(25)18(26)8-15/h4-9,12,16H,10-11,13H2,1-3H3,(H,27,30,31)/t16-/m1/s1
Standard InChI Key: HVIGNZUDBVLTLU-MRXNPFEDSA-N
Molfile:
RDKit 2D
36 40 0 0 0 0 0 0 0 0999 V2000
31.2169 -22.9061 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.2158 -23.7297 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.9280 -24.1428 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
32.6418 -23.7293 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.6389 -22.9025 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
31.9262 -22.4972 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.3542 -24.1409 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
34.0654 -23.7271 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.8130 -24.0612 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
35.3588 -23.4490 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
34.9491 -22.7377 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.1460 -22.9090 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.9839 -24.8645 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.5050 -22.4977 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.9243 -21.6760 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.5880 -21.1895 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.2576 -21.1935 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
31.5077 -20.4114 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.3293 -20.4095 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
32.7382 -19.7004 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.3260 -18.9887 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.5044 -18.9906 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
31.0951 -19.7042 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.2737 -19.7073 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
31.0949 -18.2834 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.5025 -17.5710 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.3235 -17.5721 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.7352 -16.8605 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.3215 -16.1482 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.4959 -16.1520 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.0920 -16.8641 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.0830 -15.4468 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
32.7275 -15.4391 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
32.7332 -18.2802 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.5504 -18.2787 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
33.9577 -17.5702 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
4 7 1 0
7 8 1 0
8 9 1 0
9 10 1 0
10 11 2 0
11 12 1 0
12 8 2 0
9 13 1 0
1 14 1 0
15 16 2 0
16 19 1 0
18 17 2 0
17 15 1 0
6 15 1 0
18 19 1 0
18 23 1 0
19 20 1 0
20 21 1 0
21 22 1 0
22 23 1 0
23 24 2 0
22 25 1 0
25 26 1 0
26 27 2 0
27 28 1 0
28 29 2 0
29 30 1 0
30 31 2 0
31 26 1 0
30 32 1 0
29 33 1 0
21 34 1 1
34 35 1 0
35 36 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 494.51Molecular Weight (Monoisotopic): 494.1990AlogP: 3.07#Rotatable Bonds: 7Polar Surface Area: 102.99Molecular Species: NEUTRALHBA: 9HBD: 1#RO5 Violations: ┄HBA (Lipinski): 10HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 12.64CX Basic pKa: 3.04CX LogP: 3.25CX LogD: 3.25Aromatic Rings: 4Heavy Atoms: 36QED Weighted: 0.42Np Likeness Score: -1.64
References 1. Ward RA, Anderton MJ, Bethel P, Breed J, Cook C, Davies EJ, Dobson A, Dong Z, Fairley G, Farrington P, Feron L, Flemington V, Gibbons FD, Graham MA, Greenwood R, Hanson L, Hopcroft P, Howells R, Hudson J, James M, Jones CD, Jones CR, Li Y, Lamont S, Lewis R, Lindsay N, McCabe J, McGuire T, Rawlins P, Roberts K, Sandin L, Simpson I, Swallow S, Tang J, Tomkinson G, Tonge M, Wang Z, Zhai B.. (2019) Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)., 62 (24): [PMID:31710489 ] [10.1021/acs.jmedchem.9b01295 ]